News

Who would be the optimal candidate to receive focused ultrasound to treat obsessive-compulsive disorder?

Perhaps, in our modern arguments over the reality of mental illness, we are merely reinventing the wheel—or maybe, just spinning our wheels.

"This is the moment my therapist would cross his legs, look into my eyes, and wait for me to reveal something."

Learn more about Alto Neuroscience's ALTO-300, in ongoing phase 2b trials as an adjunct treatment for major depressive disorder.

What does Han Kang’s 2007 book reveal about psychiatric diagnoses and societal pressure?

Need CME credit? We've got a present for you!

What do these 12 Christmas symbols mean psychologically?

With MM120 in phase 3 in the MindMed trial, what place do psychedelics hold in psychiatry?

The holidays are a good time for forgiveness.

The harmful psychiatrists… who are they?

An FDA committee recently decided the clozapine REMS protocol was no longer necessary. How will this impact clinicians?

An observational cohort study found patients at less risk of hospitalization for alcohol use disorder when also being treated with a GLP-1 agonist anti-diabetic/obesity agent.

In this CME article, learn more about recent developments with lithium as they relate to renal issues.

Every song tells a story.

Do you feel burnt out heading into the holidays? Tell us about it!

Patients with treatment resistant obsessive-compulsive disorder and depression may now experience some relief using focused ultrasound.

"They don't teach the talking treatment anymore..."

Questions before the New Year…

An expert shares more about the recent data on NeuroStar advanced TMS. Learn more here.

A recent longitudinal, retrospective study aimed to examine antipsychotic prescribing and rehospitalization rates in a forensic psychiatric sample.

Remembering child psychiatrists…

New positive topline results from an open-label phase 2a study of IV psilocin benzoate in patients with major depressive disorder showed that the treatment delivers rapid, lasting antidepressant effects for up to 3 months following a single dose.

This article is sponsored by Otsuka America Pharmaceutical, Inc. and Lundbeck, for which Dr. Ilan Melnick is a paid consultant.

Researchers investigated the link between psychosis, criminal sanctions, and mortality rates following discharge from a hospital for acute psychosis.

Would you like to be featured in an upcoming print issue? Submit an article on child & adolescent psychiatry!

MindMed announced phase 3 study of psychedelic MM120 for Generalized Anxiety Disorder.

Extreme risk protection orders may be an effective suicide prevention tool.

What are the psychological challenges of this upcoming holiday season?

MindMed announced phase 3 of a trial testing a new treatment for generalized anxiety disorder is under way.